Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 13Thoracic 2Other neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Melanoma 16Neoplasm Metastasis 4Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma, Cutaneous Malignant 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Hodgkin Disease 1Histiocytoma 1Head and Neck Neoplasms 1Fibrosarcoma 1Esophageal Neoplasms 1Dermatofibrosarcoma 1

Interventions

pembrolizumab 24Nivolumab 9atezolizumab 8Drug Therapy 6cemiplimab 5Immune Checkpoint Inhibitors 5fludarabine 4Radiotherapy 4Paclitaxel 4Interleukin-2 4Cyclophosphamide 4Docetaxel 3fludarabine phosphate 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Radiosurgery 2Radiation 2Patient Reported Outcome Measures 2Oncolytic Virotherapy 2Ipilimumab 2Immunotherapy 2Gemcitabine 2Filgrastim 2Cisplatin 2Cetuximab 2Carboplatin 2vocimagene amiretrorepvec 1venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Albumin-Bound Paclitaxel × Dermatologic × Clear all
NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Seagen Inc.

Phase 1 Terminated
159 enrolled
DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡